Answers are grounded in this paper and cite their sources.
Oral RBV appears to be a safe and cost-effective alternative to aerosolized RBV for the management of RSV infection in immunocompromised patients. Larger studies are needed to validate the safety and efficacy of this approach.
No takes yet. Share an insight, caveat, or question.
Trang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: